Bioadaptives (BDPT) Accounts Payables (2013 - 2026)

Bioadaptives has disclosed Accounts Payables across 13 years of filings, most recently posting $248886.0 for Q1 2026.

• Accounts Payables for Q1 2026 came in at $248886.0, up 26.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $248886.0 (up 26.46% YoY), and the FY2025 annual result was $232725.0, up 29.68% from the prior year.
• Accounts Payables came in at $248886.0 for Q1 2026 at Bioadaptives, up from $232725.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $473501.0 in Q3 2024 to a low of $179458.0 in Q4 2024.
• The 5-year median for Accounts Payables is $400244.0 (2022), against an average of $347642.4.
• Across the five-year window, Accounts Payables soared 467.47% in 2022 and plunged 59.54% in 2024, its largest moves.
• Bioadaptives' Accounts Payables stood at $409920.0 in 2022, then rose by 8.21% to $443579.0 in 2023, then slumped by 59.54% to $179458.0 in 2024, then advanced by 29.68% to $232725.0 in 2025, then advanced by 6.94% to $248886.0 in 2026.
• The last three Accounts Payables figures came in at $248886.0 (Q1 2026), $232725.0 (Q4 2025), and $230768.0 (Q3 2025), per Business Quant data.